Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C

被引:131
作者
Mauro, Ezequiel [1 ,2 ]
Crespo, Gonzalo [1 ]
Montironi, Carla [3 ]
Londono, Maria-Carlota [4 ]
Hernandez-Gea, Virginia [5 ]
Ruiz, Pablo [1 ]
Sastre, Lydia [1 ]
Lombardo, Julissa [1 ]
Marino, Zoe [4 ]
Diaz, Alba [3 ]
Colmenero, Jordi [1 ]
Rimola, Antoni [1 ]
Carlos Garcia-Pagan, Juan [5 ]
Brunet, Merce [6 ]
Forns, Xavier [4 ]
Navasa, Miquel [1 ]
机构
[1] Hosp Clin Barcelona, Liver Transplant Unit, Liver Unit, IDIBAPS,CIBERehd, Villarroel 170, Barcelona 08036, Spain
[2] Hosp Italiano Buenos Aires, Liver Unit, Buenos Aires, DF, Argentina
[3] Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain
[4] Hosp Clin Barcelona, Liver Unit, IDIBAPS, CIBERehd, Barcelona, Spain
[5] Hosp Clin Barcelona, Barcelona Hemodynam Lab, Liver Unit, IDIBAPS,CIBERehd, Barcelona, Spain
[6] Univ Barcelona, Hosp Clin, Pharmacol & Toxicol, IDIBAPS,CIBERehd, Barcelona, Spain
关键词
SOCIETY CONSENSUS STATEMENT; SOFOSBUVIR PLUS RIBAVIRIN; ANTIVIRAL THERAPY; VIRUS-INFECTION; TRANSPLANT RECIPIENTS; VIRAL-HEPATITIS; CIRRHOSIS; HYPERTENSION; DISEASE; PROGRESSION;
D O I
10.1002/hep.29557
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Sustained virological response (SVR) improves survival in post-liver transplant (LT) recurrent hepatitis C. However, the impact of SVR on fibrosis regression is not well defined. In addition, the performance of noninvasive methods to evaluate the presence of fibrosis and portal hypertension (PH) post-SVR has been scarcely evaluated. We aimed to investigate the degree of fibrosis regression (decrease 1 METAVIR stage) after-SVR and its associated factors in recurrent hepatitis C, as well as the diagnostic capacity of noninvasive methods in the assessment of liver fibrosis and PH after viral clearance. We evaluated 112 hepatitis C virus-infected LT recipients who achieved SVR between 2001 and 2015. A liver biopsy was performed before treatment and 12 months post-SVR. Hepatic venous pressure gradient (HVPG), liver stiffness measurement (LSM), and Enhanced Liver Fibrosis (ELF) score were also determined at the same time points. Sixty-seven percent of the cohort presented fibrosis regression: 43% in recipients with cirrhosis and 72%-85% in the remaining stages (P = 0.002). HVPG, LSM, and ELF significantly decreased post-SVR. Liver function significantly improved, and survival was significantly better in patients achieving fibrosis regression. Baseline HVPG and LSM as well as decompensations before therapy were independent predictors of fibrosis regression. One year post-SVR, LSM had a high diagnostic accuracy to discard the presence of advanced fibrosis (AF) and clinically significant PH (AUROC, 0.902 and 0.888). Conclusion: In conclusion, SVR post-LT induces fibrosis regression in most patients, leading to significant clinical benefits. Pretreatment HVPG and LSM are significant determinants of the likelihood of fibrosis regression. Finally, LSM accurately predicts the presence of AF and PH 1 year after SVR and thus can be used to determine monitoring strategies. (Hepatology 2018;67:1683-1694).
引用
收藏
页码:1683 / 1694
页数:12
相关论文
共 46 条
[1]   Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis [J].
Akhtar, Ehsaan ;
Manne, Vignan ;
Saab, Sammy .
LIVER INTERNATIONAL, 2015, 35 (01) :30-36
[2]  
[Anonymous], 2015, J HEPATOL, V63, P237, DOI 10.1016/j.jhep.2015.04.006
[3]  
BEDOSSA P, 1994, HEPATOLOGY, V20, P15
[4]  
Berg T, 2017, J HEPATOL, V373, P303
[5]   Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence [J].
Bizollon, T ;
Ahmed, SNS ;
Radenne, S ;
Chevallier, M ;
Chevallier, P ;
Parvaz, P ;
Guichard, S ;
Ducerf, C ;
Baulieux, J ;
Zoulim, F ;
Trepo, C .
GUT, 2003, 52 (02) :283-287
[6]   PORTAL-HYPERTENSION [J].
BOSCH, J ;
NAVASA, M ;
GARCIAPAGAN, JC ;
DELACY, AM ;
RODES, J .
MEDICAL CLINICS OF NORTH AMERICA, 1989, 73 (04) :931-953
[7]   Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation:: A randomized controlled study [J].
Carrion, Jose A. ;
Navasa, Miquel ;
Garcia-Retortillo, Montserrat ;
Garcia-Pagan, Juan Carlos ;
Crespo, Gonzalo ;
Bruguera, Miquel ;
Bosch, Jaime ;
Forns, Xavier .
GASTROENTEROLOGY, 2007, 132 (05) :1746-1756
[8]  
Castera L, 2016, J HEPATOL, V64, P232, DOI 10.1016/j.jhep.2015.10.011
[9]   Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease [J].
Charlton, Michael ;
Everson, Gregory T. ;
Flamm, Steven L. ;
Kumar, Princy ;
Landis, Charles ;
Brown, Robert S., Jr. ;
Fried, Michael W. ;
Terrault, Norah A. ;
O'Leary, Jacqueline G. ;
Vargas, Hugo E. ;
Kuo, Alexander ;
Schiff, Eugene ;
Sulkowski, Mark S. ;
Gilroy, Richard ;
Watt, Kymberly D. ;
Brown, Kimberly ;
Kwo, Paul ;
Pungpapong, Surakit ;
Korenblat, Kevin M. ;
Muir, Andrew J. ;
Teperman, Lewis ;
Fontana, Robert J. ;
Denning, Jill ;
Arterburn, Sarah ;
Dvory-Sobol, Hadas ;
Brandt-Sarif, Theo ;
Pang, Phillip S. ;
McHutchison, John G. ;
Reddy, K. Rajender ;
Afdhal, Nezam .
GASTROENTEROLOGY, 2015, 149 (03) :649-659
[10]   Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C [J].
Crespo, G. ;
Lens, S. ;
Gambato, M. ;
Carrion, J. A. ;
Marino, Z. ;
Londono, M-C ;
Miquel, R. ;
Bosch, J. ;
Navasa, M. ;
Forns, X. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (02) :375-383